- Investing Ideas
- Indian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Indian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
7
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
7 companies
Alembic Pharmaceuticals
Market Cap: ₹141.5b
An integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally.
APLLTD
₹720.00
7D
-5.5%
1Y
-27.7%
Aarti Pharmalabs
Market Cap: ₹58.2b
Manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally.
AARTIPHARM
₹642.35
7D
-12.3%
1Y
-27.8%
Lincoln Pharmaceuticals
Market Cap: ₹12.2b
Engages in manufacturing and trading of pharmaceutical products in India.
531633
₹611.40
7D
-14.8%
1Y
11.8%
Haleos Labs
Market Cap: ₹4.3b
Engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India.
HALEOSLABS
₹1,423.30
7D
-14.5%
1Y
10.1%
Sotac Pharmaceuticals
Market Cap: ₹1.2b
Engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India.
SOTAC
₹111.00
7D
0%
1Y
-11.9%
Par Drugs and Chemicals
Market Cap: ₹1.1b
Develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India.
PAR
₹89.31
7D
-3.2%
1Y
-12.8%
Vineet Laboratories
Market Cap: ₹658.2m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India.
VINEETLAB
₹34.27
7D
-2.0%
1Y
8.7%